Aignostics
AI pathology at scale
Berlin, New York, Germany
Aignostics, founded in 2018, develops explainable AI foundation models for digital pathology and computational biomarker discovery. The company is headquartered in Berlin, Germany, with an additional office in New York, United States.
How We Help
Problem Statement
Biopharmaceutical companies and pathologists face challenges in analyzing complex multi-modal pathology data to derive transformative insights for drug discovery, diagnostics, and treatment development across various disease areas.
Core Technology
explainable AI foundation models
Key Differentiators
Access to pathology samples and multimodal data from over 30 million patients
Clinical Focus
Tumor Microenvironment Profiling
Company Info
- Business Model
- B2B
- Founded
- 2018
- Total Funding
- 55,000,000
- Website
- www.aignostics.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
ISO 13485 and ISO 27001 certified. GCP-ready platform. Atlas 2 foundation model (co-developed with Mayo Clinic) ranks #1 across 80 public benchmarks with 2B parameters and 5M+ slide training dataset. Published research in peer-reviewed journals. Research-use only; clinical deployment pathway underway.
MedStartr Index Score
?What do you think of Aignostics?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.